Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02088034 · ClinicalTrials.gov registry record · Phase 4

Intervention to Promote Weight Loss in Latinas At-risk for Diabetes

A Phase 4 study of Diabetes, sponsored by Temple University.

Completed
Registry status
Phase 4
Development phase
92
Enrollment target
1
Study location

NCT02088034 is a Phase 4 study of Diabetes that has completed, run by Temple University. The registered enrollment target is 92 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02088034, a Phase 4 study of Diabetes, has completed, sponsored by Temple University.

COMPLETED
Registry status
Phase 4
Development phase
92 participants
Enrollment target
1
Study location

Study Summary

The overarching goal of this project is to develop and test a behavioral intervention delivered by promotoras to help at-risk Latinas lose weight and prevent diabetes.

Conditions Studied

Interventions

  • OTHER Usual Care
  • BEHAVIORAL Promotora-led Intervention
  • DRUG Metformin Therapy

Study Locations (1)

Pennsylvania

  • Temple University - Center for Obesity Research and Education - Philadelphia

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2013-09
Est. Completion 2016-02
Phase Phase 4

Sponsor

Temple University

163 total trials

What the Registry Record Tells You About NCT02088034

The ClinicalTrials.gov registry entry for NCT02088034 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (97% lower). The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Usual Care is the first listed.

NCT02088034 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02088034 about?

NCT02088034 is a clinical study titled "Intervention to Promote Weight Loss in Latinas At-risk for Diabetes". The overarching goal of this project is to develop and test a behavioral intervention delivered by promotoras to help at-risk Latinas lose weight and prevent diabetes.

What is the current status of trial NCT02088034?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2013-09. Estimated completion is 2016-02.

What conditions does trial NCT02088034 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT02088034?

The interventions under investigation include: Usual Care (OTHER), Promotora-led Intervention (BEHAVIORAL), Metformin Therapy (DRUG).

Who is sponsoring clinical trial NCT02088034?

This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02088034 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.